A5053009011- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Advanced Radiotherapy Techniques
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Inflammatory Biomarkers in Disease Prognosis
- Medical Imaging Techniques and Applications
- HER2/EGFR in Cancer Research
- Cancer Diagnosis and Treatment
- Radiation Dose and Imaging
- Occupational and environmental lung diseases
- Immune cells in cancer
- Pleural and Pulmonary Diseases
- Cancer Treatment and Pharmacology
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- Metastasis and carcinoma case studies
- Flood Risk Assessment and Management
- Brain Metastases and Treatment
- Breast Cancer Treatment Studies
Fondazione IRCCS Istituto Nazionale dei Tumori
2018-2024
University of Milan
1981-2019
University of Perugia
2017-2019
IRCCS Ospedale San Raffaele
2019
Azienda Ospedaliera di Perugia
2016-2018
Ospedale Santa Maria
2016-2018
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2015-2016
Azienda Ospedaliero Universitaria Maggiore della Carita
2015-2016
Azienda Ospedaliera di Desio e Vimercate
2016
Università Cattolica del Sacro Cuore
2004
Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR)) score, a clinical/biochemical prognostic 154 patients treated with second/further-line immunotherapy. This study’s aim was to validate score different population group. Methods: 193 were...
(1) Background: In advanced non-small cell lung cancer (aNSCLC), programmed death ligand 1 (PD-L1) remains the only biomarker for candidate patients to immunotherapy (IO). This study aimed at using artificial intelligence (AI) and machine learning (ML) tools improve response efficacy predictions in aNSCLC treated with IO. (2) Methods: Real world data blood microRNA signature classifier (MSC) were used. Patients divided into responders (R) non-responders (NR) determine if overall survival of...
Introduction Artificial Intelligence (AI) methods are being increasingly investigated as a means to generate predictive models applicable in the clinical practice. In this study, we developed model predict efficacy of immunotherapy (IO) patients with advanced non-small cell lung cancer (NSCLC) using eXplainable AI (XAI) Machine Learning (ML) methods. Methods We prospectively collected real-world data from an NSCLC condition receiving immune-checkpoint inhibitors (ICIs) either single agent or...
The investigation of multiple molecular targets with next-generation sequencing (NGS) has entered clinical practice in oncology, yielding to a paradigm shift from the histology-centric approach mutational model for personalized treatment. Accordingly, most drugs recently approved oncology are coupled specific biomarkers. One potential tool implementing precision daily is represented by Molecular Tumor Board (MTB), multidisciplinary team whereby pathologists, biologists, bioinformaticians,...
Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality life over docetaxel in patients with KRASp.G12C-mutated advanced non-small-cell lung cancer (NSCLC) within the CodeBreak-200 study. Here we report real-world efficacy tolerability data from NSCLC who received sotorasib Italian expanded access program (EAP).
Abstract. This study describes an analysis carried out within the European community project "ALARM" (Assessment of Landslide Risk and Mitigation in Mountain Areas, 2004) on landslide risk assessment municipality Corvara Badia, Italy. mountainous area, located central Dolomites (Italian Alps), poses a significant hazard to several man-made natural objects. Three parameters for determining were analysed as aid preparedness mitigation planning: event occurrence probability, elements at risk,...
Background Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) <50%. Although single-agent pembrolizumab has also demonstrated some activity in this setting, no reliable biomarkers yet exist selecting likely to respond immunotherapy. The main purpose study was identify potential new associated progression-free-survival (PFS) within a multiomics analysis. Methods PEOPLE (NTC03447678)...
Introduction: Several anaplastic lymphoma kinase (ALK) tyrosine inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With increasing number target therapies available, optimal sequence is yet to be defined, as resistance profiles may evolve over time in response sequential ALK...
•Largest dataset of NSCLC with uncommon EGFR alterations treated osimertinib.•Best outcomes compound uncommon–common mutations and G719X, L861X, or S768I.•Heterogeneous activity rarer mutations; no response at E709 residue.•Confirmed in the central nervous system, intracranial ORR 58%.•Amplification MET, TP53 mutations, E709K are putative mechanisms resistance. BackgroundOsimertinib represents standard care for treatment advanced non-small-cell lung cancer (NSCLC) harboring classical...
Breast cancer metastases to the gastrointestinal tract are very rare occurrences. Among histological subtypes of breast cancer, invasive lobular carcinomas have a high capacity metastasis uncommon sites including stomach. Conversely, there has not been sufficient evidence supporting gastric ductal carcinoma. Herein, we report unique case metastatic carcinoma mimicking primary linitis plastica in male patient, particularly focusing on clinical and pathological features presentation. Moreover,...